tirzepatide
PulseAugur coverage of tirzepatide — every cluster mentioning tirzepatide across labs, papers, and developer communities, ranked by signal.
- 2026-05-11 product_launch ShengNuo Bio's tirzepatide API successfully completed its filing with the US FDA. source
3 day(s) with sentiment data
-
GLP-1 drugs fuel luxury spending but expose fashion's size inclusivity gap
The luxury sector is experiencing a complex shift influenced by the increasing adoption of GLP-1 weight-loss medications. While overall sector growth has seen a slight dip, these medications are driving consumption as i…
-
GLP-1 weight-loss drugs drive major climate impact by cutting food demand
The widespread adoption of GLP-1 medications for weight loss is having a significant, albeit unintended, impact on the climate by reducing demand for carbon-intensive foods. As more Americans use drugs like semaglutide …
-
Government healthcare cost projections struggle with GLP-1 drug spending
Government healthcare cost projections for GLP-1 medications like Ozempic and Mounjaro are proving difficult to accurately forecast. Agencies like CMS and CBO rely on historical data and assumptions that may not account…
-
France to reimburse anti-obesity drugs for first time in EU
France is set to become the first European Union country to reimburse anti-obesity medications for severely obese patients starting mid-June. The government estimates this initiative will cost approximately €100 million…
-
GLP-1 drugs show anti-inflammatory benefits beyond weight loss
GLP-1 medications like Ozempic and Wegovy, known for weight loss, are showing promise in treating inflammation and tissue damage, particularly in osteoarthritis. A study in Cell Metabolism found semaglutide reduced infl…
-
GLP-1 drugs may reduce cancer progression, new study suggests
New research presented at the American Society of Clinical Oncology meeting suggests that GLP-1 medications, commonly used for diabetes and weight loss, may also reduce the progression of certain cancers. A study analyz…
-
ShengNuo Bio's tirzepatide API clears US FDA filing
ShengNuo Bio announced that its tirzepatide active pharmaceutical ingredient has completed its filing with the US FDA, making it available for use by drug manufacturers. This GLP-1/GIP dual receptor agonist is intended …
-
Users split on AI for fitness: helpful tool or risky advice?
A recent article explores the varied ways individuals are incorporating AI into their fitness routines, with user experiences ranging from high satisfaction to outright disdain. While some find AI-generated workout and …
-
Browser automation platforms Simplex and Finic launch open-source tools
Simplex and Finic are two new platforms designed to automate browser-based tasks for developers. Simplex focuses on streamlining the prior authorization process for healthcare providers by integrating with existing clin…